SENS. CHAFEE/PRYOR GENERIC PATENT AMENDMENT TO BE OFFERED ON FLOOR, PRYOR VOWS DURING FINANCE COMMITTEE MARKUP; MEDICAID DRUG REBATE SUNSET REPEALED
Generic companies that have made a substantial investment in a product in anticipation of patent expiration would be permitted to market during the "delta period" between the old patent expiration date set by the Waxman/Hatch Act and the new expiration date set by the General Agreement on Tariffs & Trade under an amendment to be introduced on the Senate floor by Sen. Pryor (D-Ark.).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth